Abacus dx now distributing Devyser in Australia and New Zealand
Abacus dx is pleased to announce that we have been appointed the exclusive distributor for Devyser in Australia and New Zealand.
Devyser specialise in diagnostic kits for complex DNA testing within hereditary diseases, oncology and transplantation. Their products are used to guide targeted cancer therapies, to enable rapid prenatal diagnostics and post-transplant follow up.
Devyser BRCA for NGS
Included in their portfolio is the Devyser BRCA and Devyser HBOC NGS kits*, rapid targeted NGS library preparation assays intended for the detection of variants in BRCA1, BRCA2 and 12 additional genes where mutations are known to significantly increase the risk of developing breast and/or ovarian cancer.
- Devyser BRCA and Devyser HBOC kits can be used simultaneously as a first-line protocol for the analysis of 14 highly relevant HBOC-associated genes
- Devyer HBOC kit can also be used as a follow-up after negative BRCA testing with Devyser BRCA
Devyser BRCA is intended for the detection of germline and somatic sequence variants in the coding regions of BRCA1 and BRCA2 genes.
Key Features:
- Full coding exon coverage of BRCA1 and BRCA2 and adjacent exon-intron boundaries
- Detection of SNVs, indels and exon spanning CNVs^
- Short amplicon design optimal for fragmented DNA from FFPE samples
- One kit for both blood and FFPE samples
- Identical workflow for all sample types
^CNV detection is not validated for FFPE samples
Devyser RHD test kit
Another exciting product is the Devyser RHD test kit* which is used to determine fetal RHD status from maternal plasma as early as gestation week 10. This kit allows for non-invasive detection of fetal RHD in an assay design which simplifies workflow, automation and analysis and has a ≥99.7% correlation to Rhesus serology of the newborn.
Key Features:
- Sensitive and specific RHD determination: ≥99.7% diagnostic sensitivity, ≥99.5% diagnostic specificity
- Single exon design
- Treat only the RHD-negative mothers at risk
- Non-invasive test
*Please check regulatory status in your country
